Aquestive Therapeutics - AQST Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.70
  • Forecasted Upside: 750.88 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.14
+0 (0.00%)

This chart shows the closing price for AQST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aquestive Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AQST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AQST

Analyst Price Target is $9.70
▲ +750.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aquestive Therapeutics in the last 3 months. The average price target is $9.70, with a high forecast of $17.00 and a low forecast of $5.00. The average price target represents a 750.88% upside from the last price of $1.14.

This chart shows the closing price for AQST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Aquestive Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/6/2022OppenheimerInitiated CoverageOutperform$8.50Low
9/6/2022HC WainwrightLower TargetBuy$6.00 ➝ $5.00Low
8/30/2022Alliance Global PartnersInitiated CoverageBuy$10.00Low
8/15/2022HC WainwrightBoost TargetBuy$5.00 ➝ $6.00Low
6/21/2022HC WainwrightLower TargetBuy$8.00 ➝ $5.00Low
5/31/2022HC WainwrightLower TargetBuy$14.00 ➝ $8.00Medium
5/18/2022JMP SecuritiesReiterated RatingBuy$17.00Medium
3/10/2022WedbushLower TargetOutperform$26.00 ➝ $8.00High
12/23/2021HC WainwrightReiterated RatingBuy$14.00High
12/22/2021WedbushReiterated RatingBuy$26.00Medium
7/26/2021HC WainwrightReiterated RatingBuy$14.00Low
6/24/2021WedbushReiterated RatingBuy$30.00Medium
3/29/2021Lake Street CapitalReiterated RatingMarket Perform ➝ Buy$7.00High
3/15/2021HC WainwrightReiterated RatingBuy$14.00High
1/22/2021HC WainwrightReiterated RatingBuy$14.00Low
9/28/2020BMO Capital MarketsLower Target$18.00 ➝ $13.00High
9/28/2020Lake Street CapitalBoost TargetPositive ➝ Buy$7.00 ➝ $10.00High
9/28/2020HC WainwrightLower TargetBuy$15.00 ➝ $14.00High
9/28/2020Royal Bank of CanadaLower TargetOutperform$8.00 ➝ $7.00High
9/28/2020JMP SecuritiesLower TargetOutperform$23.00 ➝ $17.00High
9/2/2020WedbushReiterated RatingBuy$33.00Medium
8/13/2020WedbushReiterated RatingBuy$33.00Medium
8/6/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
7/6/2020WedbushReiterated RatingBuy$31.00Medium
6/30/2020HC WainwrightReiterated RatingBuy$15.00Medium
6/30/2020WedbushReiterated RatingBuy$31.00Medium
5/22/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $15.00High
5/6/2020WedbushReiterated RatingBuy$31.00High
4/22/2020WedbushReiterated RatingBuy$31.00Medium
4/21/2020HC WainwrightReiterated RatingBuy$13.00Medium
4/5/2020WedbushReiterated RatingBuy$31.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
3/22/2020WedbushReiterated RatingBuy$31.00Low
3/15/2020WedbushReiterated RatingBuy$36.00 ➝ $31.00High
2/10/2020WedbushBoost TargetOutperform$35.00 ➝ $36.00High
2/3/2020WedbushReiterated RatingBuy$35.00Medium
1/13/2020BMO Capital MarketsLower TargetOutperform$19.00 ➝ $18.00High
1/6/2020WedbushReiterated RatingBuy$35.00N/A
12/27/2019Lake Street CapitalReiterated RatingBuy$11.00 ➝ $10.00High
12/18/2019HC WainwrightReiterated RatingBuy$13.00Low
12/16/2019WedbushReiterated RatingBuy$37.00 ➝ $34.00Low
12/2/2019WedbushReiterated RatingBuy$37.00Low
12/2/2019HC WainwrightReiterated RatingBuy$12.00 ➝ $14.00High
11/25/2019WedbushReiterated RatingBuy$37.00High
10/16/2019WedbushReiterated RatingBuy$34.00High
9/30/2019WedbushReiterated RatingBuy$34.00Medium
7/5/2019WedbushSet TargetBuy$31.00Low
5/8/2019WedbushSet TargetBuy$31.00High
4/22/2019HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
3/22/2019WedbushSet TargetBuy$30.00Low
3/15/2019BMO Capital MarketsLower TargetIn-Line ➝ Outperform$24.00 ➝ $21.00High
2/20/2019Lake Street CapitalReiterated RatingBuyHigh
1/3/2019Lake Street CapitalInitiated CoverageBuy ➝ Buy$14.00Low
12/20/2018WedbushSet TargetBuy AQST$30.00High
12/14/2018WedbushReiterated RatingBuy$30.00Medium
12/6/2018WedbushBoost TargetOutperform ➝ Outperform$29.00 ➝ $30.00High
11/7/2018Royal Bank of CanadaSet TargetBuy$24.00Low
10/25/2018WedbushSet TargetBuy$34.00Medium
10/10/2018WedbushSet TargetBuy$34.00Medium
9/12/2018WedbushInitiated CoverageOutperform$33.00Medium
8/20/2018Royal Bank of CanadaInitiated CoverageOutperform$23.00Low
8/20/2018JMP SecuritiesInitiated CoverageOutperform$29.00Low
8/20/2018BMO Capital MarketsInitiated CoverageOutperformLow
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
4/8/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Aquestive Therapeutics logo
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: $1.14
Low: $1.08
High: $1.14

50 Day Range

MA: $1.24
Low: $0.82
High: $1.73

52 Week Range

Now: $1.14
Low: $0.62
High: $6.40

Volume

3,634 shs

Average Volume

1,164,072 shs

Market Capitalization

$60.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Aquestive Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Aquestive Therapeutics in the last twelve months: Alliance Global Partners, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., and Wedbush.
View the latest analyst ratings for AQST.

What is the current price target for Aquestive Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Aquestive Therapeutics in the last year. Their average twelve-month price target is $9.70, suggesting a possible upside of 750.9%. JMP Securities has the highest price target set, predicting AQST will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Aquestive Therapeutics in the next year.
View the latest price targets for AQST.

What is the current consensus analyst rating for Aquestive Therapeutics?

Aquestive Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AQST will outperform the market and that investors should add to their positions of Aquestive Therapeutics.
View the latest ratings for AQST.

What other companies compete with Aquestive Therapeutics?

How do I contact Aquestive Therapeutics' investor relations team?

Aquestive Therapeutics' physical mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company's listed phone number is (908) 941-1900 and its investor relations email address is [email protected] The official website for Aquestive Therapeutics is www.aquestive.com. Learn More about contacing Aquestive Therapeutics investor relations.